Published in:
01-11-2015 | Original Article
Platelet Activation Markers Are Associated with Crohn’s Disease Activity in Patients with Low C-Reactive Protein
Authors:
Hiroshi Takeyama, Tsunekazu Mizushima, Hideki Iijima, Shinzaki Shinichiro, Mamoru Uemura, Junichi Nishimura, Taishi Hata, Ichiro Takemasa, Hirofumi Yamamoto, Yuichiro Doki, Masaki Mori
Published in:
Digestive Diseases and Sciences
|
Issue 11/2015
Login to get access
Abstract
Background
In assessing Crohn’s disease (CD) activity, C-reactive protein (CRP) is an important indicator of inflammation; however, it is not necessarily associated with the Crohn’s Disease Activity Index (CDAI), particularly in patients with low CRP. Recently, platelet activation factors have been recognized due to their importance in the inflammatory response. In this study, we examined associations between the CDAI and platelet factor 4 (PF-4), β-thromboglobulin (β-TG), and other coagulation and fibrinolysis factors.
Aims
We aimed to find a new marker for evaluating disease activity in patients with CD and low CRP.
Methods
Nine markers, including CRP, platelet count, white blood cell count, fibrin and fibrinogen degradation product, fibrinogen, thrombin–antithrombin complex, prothrombin fragments 1 + 2, PF-4, and β-TG were evaluated in 47 patients with CD and low CRP (<1.0 mg/dl). Patients were assigned to high or low disease activity groups, CDAI-H (CDAI ≥ 150) and CDAI-L (CDAI < 150), respectively.
Results
CDAI-H exhibited significantly higher PF-4 and β-TG levels than CDAI-L (P < 0.01). Other markers were not significantly different between groups. CDAI was positively correlated with the levels of PF-4 and β-TG (P = 0.0033 and 0.0024; r = 0.4202 and 0.4321, respectively). Receiver operating characteristic curve analyses of PF-4 and β-TG showed high sensitivity (61.9 and 81 %, respectively) and specificity (84.7 and 69.2 %, respectively) for diagnosing active CD.
Conclusion
Among eight potential markers, PF-4 and β-TG were the most highly correlated with CDAI in patients with CD and low CRP. PF-4 and β-TG levels showed promise as new markers for assessing CD in patients with low CRP.